Summary: Primary immune thrombocytopenia (ITP) is one of the most common bleeding disorders of childhood. In most cases, it presents with sudden widespread bruising and petechiae in an otherwise well child. Thought to be mainly a disorder of antibodymediated platelet destruction, ITP can be self-limited or develop into a chronic condition. In this review, we discuss current concepts of the pathophysiology and treatment approaches to pediatric ITP.
With marginal responses to both WinRho and IVIg, it was decided to examine the bone marrow to ensure that underlying aplasia, leukemia, or other marrow pathology was not contributing to her thrombocytopenia. Bone marrow biopsy (Fig. 1B) and aspirate (Figs. 1C, D) showed normal cellularity (80% to 90%) and trilineage hematopoeisis with adequate numbers of megakaryocytes. Corresponding flow cytometry and cytogenetics were normal and screening tests for lupus and bone marrow failure syndromes (eg, Fanconi anemia, paroxysmal nocturnal hemoglobinuria) were negative. Confident in the diagnosis of immune thrombocytopenia (ITP), we prescribed a course of prednisone (2 mg/kg/d). The platelet count gradually increased to 72,000/mL after 10 days and we attempted to wean her dose to 1 mg/kg/d. The platelet count a week later was 3000/mL, thus the prednisone dose was raised again to 2 mg/kg/d. Unfortunately, the platelet count did not exceed 10,000/mL during the next 3 weeks of prednisone (2 mg/kg/ d). Steroids were weaned, and the child was treated with rituximab (250 mg/m 2 /wk for 4 consecutive weeks). The platelet count failed to rise >14,000/mL for the following 2½ months despite intermittent dosing with WinRho. A repeat marrow examination was unremarkable. We prescribed immunosuppressive therapy with oral sirolimus and the patient's platelet count remained low (between 3000 and 13,000/mL) for the next 2 months. When her platelet count was found to be 0/mL, a dose of WinRho was given on top of sirolimus, and her platelet count rose unexpectedly to 106,000/mL, 5 days after the WinRho infusion and still on sirolimus. She maintained robust responses to WinRho administered every 3 weeks or so while on sirolimus. Roughly 5 months into sirolimus therapy and approximately 45 weeks after her initial presentation, her platelet count normalized. The child was treated with WinRho only twice more, each time with robust platelet responses. We gradually weaned the sirolimus, and she discontinued all ITP therapy 94 weeks after initial presentation. At the time of this writing, she is now approximately 1 year removed from her last dose of sirolimus and is clinically well. A graphical representation of her clinical course is included (Fig. 2) .
PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Thrombocytopenia caused by the production of autoantibodies directed against platelets is known as primary immune thrombocytopenia (ITP), previously termed idiopathic thrombocytopenic purpurae. ITP is defined as isolated thrombocytopenia (< 100,000 platelets/mL) in the absence of conditions known to reduce platelet count ( Table 1 ). The pathophysiological basis for ITP is a misdirected humoral antibody response targeted against platelets resulting in a markedly shortened life span for platelets in circulation. Instead of lasting for 8 to 10 days, circulating platelets persist only for a few hours in patients with ITP because they are rapidly cleared once coated with antibody. 6 Interference with production of platelets may also occur in ITP through suppression of megakaryocyte production in the marrow, 7 therefore, ITP is a mixed disorder of destruction and production. As new platelet production cannot keep pace with peripheral clearance, total number of circulating platelets drops and symptoms of thrombocytopenia ensue. Circulating platelets in ITP patients, although few in number, tend to be particularly effective at hemostasis, perhaps because most will have been recently released from the marrow and are fresh, large, and granular. As a result, ITP patients are far less likely to have serious bleeding than patients with similarly low platelet counts caused by other processes such as marrow failure. ITP can be diagnosed only when other causes of thrombocytopenias have been considered and reasonably excluded ( Table 1 ). The marrow is typically normal in ITP, 8 reinforcing the concept that ITP is primarily a process of premature platelet destruction rather than one of insufficient or impaired platelet production. The American Society of Hematology suggests, however, that a bone marrow examination is not routinely indicated to establish the For primary ITP to be diagnosed, disorders known to be associated with secondary thrombocytopenia must first be reasonably excluded. Please note that this is an incomplete list and although diseases have been organized into broad categories, many can lower platelet count by Z1 mechanism. [1] [2] [3] [4] [5] CMV indicates cytomegalovirus; EBV, Epstein-Barr virus; EDTA, ethylenediaminetetraacetic acid; HELLP, hemolysis, elevated Liver enzymes and low platelet count; HIV, human immunodeficiency virus; TORCH, toxoplasmosis, other, rubella, cytomegalovirus, herpes simplex virus-2; VZV, varicella zoster virus. diagnosis of ITP. 1 Likewise, testing for antiplatelet antibodies is not routinely helpful in diagnosing ITP. 1 
INCIDENCE
The peak age of diagnosis for childhood ITP is between 2 and 6 years of life and ITP affects roughly 1 in every 10,000 children. 9, 10 Incidence in boys and girls is roughly the same. 11 Many patients give a history of a preceding viral infection within a few weeks of presenting with thrombocytopenia, raising the possibility that the aberrant autoimmune response of ITP may be triggered by infection. Indeed, seasonal fluctuation in ITP incidence has been described, highest in the spring and lowest in the autumn, perhaps reflecting seasonal variation in viral illnesses. 12 ITP is highly unusual below a year of life, probably due to the immaturity of the immune system in the very young patient. Neonatal immune-mediated thrombocytopenia is almost always due to maternally derived antibody either because of maternal ITP or because of neonatal alloimmune thrombocytopenia, an alloimmune maternal humoral response against "foreign" paternally-derived antigens on platelets. 13, 14 
PRESENTATION AND WORK-UP
The typical presentation of ITP in children is acute widespread appearance of petechiae and purpurae most prominent on extensor surfaces of the skin and at sites where pressure was placed on an extremity, for example at sites of blood pressure measurement. Typically, the child will be completely well one day and then covered with petechiae and purpurae the next. It is not uncommon for patients to be referred because of suspicion of nonaccidental trauma (child abuse). In general, however, children with ITP appear well otherwise and usually are playful and interactive. Although some patients have "wet purpurae" inside the mouth, epistaxis or overt bleeding occurs in less than a third of patients. 11 ITP is a clinical diagnosis without a specific confirmatory test. To diagnose ITP, conditions known to be associated with thrombocytopenia must first be reasonably excluded (Table 1) . A careful history and physical examination are mandatory. Constitutional symptoms (fever, weight loss), pallor, pain, lymphadenopathy, hepatosplenomegaly, or jaundice suggest diagnoses other than ITP.
Suggested aspects of the diagnostic work-up for ITP are shown in Table 2 . Children with ITP generally have a completely normal complete blood count except for thrombocytopenia. The peripheral blood platelet count will typically be <100Â 10 9 /L but in practice is often much lower at presentation. In 1 study, the platelet count in newly diagnosed children with ITP was found to be <20,000/mL in over 75% of cases. 20, 21 Ironically, profound thrombocytopenia is actually reassuring as it points toward uncomplicated ITP rather than more serious diagnoses such as leukemia or bone marrow failure that usually feature more moderate platelet counts (40,000 to 90,000/mL). Serum lactate dehydrogenase and uric acid, if sent, are usually normal in ITP and may help allay concerns about leukemia or other lymphoproliferative diseases. The American Society of Hematology and several studies suggest that bone marrow examination is unnecessary for most children who present with classic features of ITP. 1, [22] [23] [24] [25] However, when atypical historical, physical, or laboratory features exist, then bone marrow examination is helpful to 
CLINICAL VARIANTS
ITP can be classified according to how long symptoms have persisted. Thus, ITP is referred to as "newly diagnosed" within 3 months of initial diagnosis, "persistent" from 3 to 12 months after diagnosis, and "chronic" if it persists beyond 12 months. 26, 27 Persistent or chronic ITP can manifest as a stuttering course of thrombocytopenia of variable severity or can simply be ITP that presented acutely but that has persisted over time. There is no way of knowing at diagnosis which clinical course a patient's ITP will take, however, patient age can be predictive. ITP affecting young children is more likely to be acute and resolving, whereas ITP in older children and adolescents has a higher risk of becoming chronic, similar to ITP in adults. [28] [29] [30] Insidious onset of symptoms or secondary ITP in association with other autoimmune disorders (such as collagen vascular disease) may also predict a chronic course. 31 Nonetheless, platelet counts will return to normal within 2 months of diagnosis in about half of children and within 3 months for almost two thirds. 32 Of those whose ITP persists for 6 months, up to a quarter will have normalization of their platelet within the next 6 months 20 and many will eventually resolve There is no "gold standard" test that could be used to diagnose ITP in children; ITP remains a diagnosis of exclusion. Most cases of ITP can be identified correctly based on history, physical findings, and targeted laboratory studies. In general, if the history, physical examination, and complete blood count are consistent with acute ITP, then the more esoteric studies may be excluded from the initial work-up and be reserved for cases of chronic or refractory thrombocytopenia or if the patient presents with atypical features. 1, 4, [15] [16] [17] [18] [19] beyond then with or without anti-immune-directed therapy. 33 
PATHOPHYSIOLOGY
A groundbreaking experiment performed in 1950 proved beyond doubt that ITP is a humoral disease associated with premature destruction of circulating platelets. In a clinical trial that could never be carried out today, Drs William Harrington and James Hollingsworth, 2 medical hematology fellows in St Louis, injected healthy subjects (including Harrington himself) with plasma derived from patients suffering from ITP. In each of 35 separate trials, plasma from patients with ITP (but not from normal controls) profoundly lowered the recipient's circulating platelet count within 30 to 60 minutes with persistence for up to 7 days. To be sure the humoral factor responsible for ITP caused destruction of platelets rather than inhibition of their formation, recipients also underwent bone marrow examinations-in each case no abnormalities in either the number or appearance of megakaryocytes was found. 34, 35 We now know that the circulating factor responsible for ITP is IgG that binds platelets and leads to their premature destruction. 36 Platelet antigens recognized in ITP include membrane glycoproteins Ia/IIa, IIIa, Ib, IIb, and IX. [37] [38] [39] Regardless of the antigen targeted, binding of IgG to the platelets encourages opsonization and phagocytosis by reticuolendothelial cells primarily in the spleen. As a result, the life span of circulating platelets, normally 8 to 10 days, is profoundly reduced to a matter of a few hours. 35 Thus, ITP clearly is associated with premature clearance of platelets in the periphery. Recent evidence suggests that platelet underproduction may also contribute to ITP. Autoantibodies may bind megakaryocytes in the marrow and interfere with their survival or differentiation. 7, 40 In addition, there is evidence that ITP is associated with impaired hepatic production of thrombopoeitin, the chief stimulant of megakaryocyte proliferation and platelet production. 41 This basic understanding of the various underlying mechanisms of disease at play in ITP explains our current treatment approaches to ITP: (1) interference with antibody production; (2) inhibition of F c receptor-mediated opsonization by splenic macrophages; (3) immunosuppression; and (4) stimulation of thrombopoeisis in the marrow.
PSYCHOSOCIAL IMPACT OF THE DISEASE
The psychosocial burdens of ITP on patients and their families can be significant, especially when ITP is longlasting. Parental concerns over serious bleeding, frequent blood testing, infusions, activity restrictions, and medication side effects are major stressors that accompany the diagnosis. Prolonged restriction of normal activities of childhood can have significant impact study by Klaassen et al 42 found that treating ITP patients with romiplostim, a thrombopoeitin agonist, significantly reduced parental psychological burden, presumably because parents were less stressed about potential bleeding in their children after platelet counts were raised. In 1 analysis of over 1000 adult ITP patients and over 1000 non-ITP controls, ITP patients scored significantly worse on a variety of lifestyle measures, including 7 of 8 SF (short form)-36 quality of life assessment domains, the Physical and Mental Summary score, and the EQ (EuroQol)-5D visual analog scale. 43 Another study found that the health-related quality of life in ITP patients was even worse than patients with cancer. 44 Therefore, although ITP can be considered to be a "benign" hematologic disorder, it is associated with significant psychological stress. To provide the most comprehensive care to children with ITP and their families, it is critical to explore the psychosocial impacts of the diagnosis on patients and their families.
THROMBOCYTOPENIC ACTIVITY PRECAUTIONS
One of the most challenging aspects to the management of a child with ITP is restricting participation in normal play and sports activities because of concerns over bleeding risk. Incidence of severe hemorrhage is actually rare in uncomplicated childhood ITP, and few internal bleeds occur unless a significant trauma or injury occurs while the patient is severely thrombocytopenic. 45 Intracranial hemorrhage occurs in only 1 in a thousand children diagnosed with ITP. 12 Nonetheless, many practitioners feel that a "common sense" approach should be adopted with regard to physical activities during periods of thrombocytopenia. In cases where the ITP persists for many weeks or months, activity limitations must be balanced with an appreciation of the many consequences of "sheltering" a child with chronic ITP, including deconditioning, weight gain, and sick child syndrome. There is great variation in how patients with ITP are counseled with respect to activity limitations. Some pediatric hematologists take the view that almost any supervised sports activity (with the possible exception of boxing) can be undertaken safely as long as proper precautions are taken (eg, wearing a helmet when batting or bicycling) and as long as the patient and parents clearly understand the risks of taking part in such activities. Other clinicians advise against participation in any activity associated with a significant risk of trauma (especially head injury) when platelet counts fall below 50,000 to 75,000/mL. For toddlers and preschool children, this might mean avoiding stairs and other climbing structures such as playground equipment or sleeping on the top bunk bed, etc.). For older children and adolescents, thrombocytopenia restrictions often involve avoiding certain sports and leisure activities ( Table 3) . Regardless of approach, medications that inhibit platelet function, most notably nonsteroidal anti-inflammatory drugs and aspirin, should be avoided while patients are thrombocytopenic.
THERAPEUTIC INTERVENTIONS
The ITP working group of the American Society of Hematology recently published updated evidenced-based practice guideline for the management of ITP. Regarding children, the committee suggested that observation alone is appropriate for pediatric ITP patients with skin manifestations (bruising and petechiae) only and no other bleeding, regardless of platelet count. 1 Recent data indicate that this "watch and wait" approach may be used in as many as 20% of children with ITP. 49 In practice, however, most hematologists and families opt to treat children with ITP, especially in the setting of a platelet count <10,000/mL or with active clinical bleeding (eg, epistaxis, menorrhagia, gingivorrhea). 50 Raising the platelet count reduces theoretical risk of serious bleeding, but importantly allows liberalization of physical activities and greatly relieves parental anxiety. Notably, neither platelet transfusions nor plasmapheresis have proven useful for treating ITP (except in situations of life-threatening or limb-threatening bleeds) as transfused platelets are usually rapidly cleared from the circulation and autoantibodies rapidly reappear in the serum after plasmapheresis. [51] [52] [53] 
MEDICAL MANAGEMENT
In general, therapy for children with chronic ITP tends to be individualized according to a variety of factors including efficacy, scheduling, toxicity, cost, and preferences of the patient, parents, and hematologist. Therapeutic interventions for ITP can be conceptualized as "front-line" or "second-line" approaches (Table 4) . Each patient's ITP course is unique, and once therapy has begun, platelet counts are generally monitored overtime to assess response. Therapeutic response criteria have been standardized (Table 5) . For some patients, only 1 treatment will be required before their ITP resolves, whereas for others (like our patient), repeated treatments may be needed over time. Presumably, the severity and course of thrombocytopenia will be determined by the strength and longevity of the antiplatelet immune response. In practice, practitioners must be somewhat flexible in their approach, and may turn from one therapy to another to optimize treatment for their particular patient. If platelets do not increase after an intervention, then either further therapy may be required (eg, a second dose of IVIg), or the diagnosis of ITP should be reevaluated. For the typical child who presents with acute ITP, front-line management includes IVIg, a short course of corticosteroids or WinRho (Anti-D) therapy in Rh-positive nonanemic children. 1 Each of these approaches interferes with antibody-mediated clearance of platelets, and most patients will respond to any of these treatments within days of administration. Although the infusion therapies (WinRho or IVIg) are more expensive, these are generally the preferred initial approach because of toxicity of glucocorticoids and theoretical concerns over partially treating unrecognized acute lymphoblastic leukemia. 25 Response to WinRho or IVIg can also help confirm the diagnosis of ITP. Antibody-based approaches such as IVIg or WinRho have a typical therapeutic window of roughly 3 weeks, coinciding with the normal half-life of IgG. The need for additional doses of IVIg or WinRho will be dictated by platelet count and how well the patient tolerated prior treatments. It should be noted that in 2010, the Food and Drug Administration issued a black box warning regarding WinRho and the potential for significant intravascular hemolysis and resultant severe anemia and multisystem organ failure. Risk seems highest in patients with preexisting hemolysis (eg, Evans syndrome), therefore screening with Coombs testing or reticulocyte count before WinRho administration seems reasonable. However, many children have been successfully treated with WinRho and severe hemolysis is a very rare adverse event. 54 Current guidelines for WinRho administration call for close monitoring of patients for at least 8 hours after infusion, with dipstick urinalysis checks for hematuria and hemoglobinuria. Glucocorticoids, the third recommended front-line therapy have long been used for ITP, 55 and platelet counts usually respond well to oral or intravenous steroids. Typically, steroids are prescribed at higher doses initially and then weaned as tolerated. Length of steroid therapy is typically for 1 to 2 weeks, but duration is often determined by platelet response. If steroids must be used chronically, then efforts should be made to find the lowest therapeutic dose to minimize toxicity.
Similar to acute ITP, children with chronic ITP may not require therapy in the absence of bleeding symptoms. However, in practice, being able to maintain a child's platelet count >40,000 to 50,000/mL allows significant liberalization of the patient's activities. It is estimated that <10% of Physical activities can be divided into 3 groups based on the degree of interpersonal contact and/or risk of trauma involved. In general, thrombocytopenic patients should probably avoid those activities with significant risk of trauma. 18, [46] [47] [48] children with ITP will require regular platelet-enhancing therapy 1 year after diagnosis. 56 For those children whose ITP endures for many months or is refractory to treatment (like our patient), ITP truly becomes a nuisance. Regular clinic visits, frequent venipuncture, and continual activity restrictions interfere with family dynamics and with normal growth and development. If a patient's history, physical findings, and laboratory studies clearly have been consistent with ITP since diagnosis, and s/he has had robust increases in the peripheral blood platelet count with each antibody-based or steroid therapy, then his/her continued thrombocytopenia most likely represents chronic ITP. If, however, there are other features that call the diagnosis of ITP into question, then a bone marrow examination should be considered to rule out disorders of impaired marrow production. 57 Various medical therapies are available to treat chronic or refractory ITP (Table 4) including rituximab (anti-CD20 therapy), immunosuppressive agents (such as the sirolimus used in our patient), chemotherapy (most notably 6-mercaptopurine), and most recently, thrombopoeitin agonists. 58 With the exception of the thrombopoeitin agonists, each of these therapies targets the wayward autoimmune response responsible for inappropriate production of antiplatelet antibodies. However, chronic immunosuppressive therapies all have significant side effects, most notably risk of severe infectious complications. The American Society of Hematology supports rituximab or high-dose dexamethasone as a preferred second-line medical approache. 1 With the development of effective noncytotoxic therapies for ITP, immunosuppressive approaches have become less popular. Rituximab, typically given as weekly infusional therapy (375 mg/m 2 ) for 4 consecutive weeks, targets CD20-expressing plasma cells, the antibody-producing mature B cells that manufacture the antibodies that perpetrate ITP. Anti-CD20 therapy, which has been used for over a decade, is generally welltolerated with few side effects. [59] [60] [61] Although rituximab therapy can cause generalized decreases in antibody production, serious infections are rare after rituximab treatment. 62 For this reason, rituximab has emerged as a widespread therapy for chronic ITP either alone or in combination with other approaches. [63] [64] [65] [66] [67] However, rituximab produces durable treatment responses in only some patients, with response rates ranging from a less than a third of patients to just over three quarters of patients. [67] [68] [69] One recent large pediatric collaborative study found an association between steroid responsiveness and rituximab efficacy, with 87.5% of steroid-responsive chronic ITP patients having good therapeutic responses to rituximab. 70 High-dose dexamethasone-typically 40 mg/d in adults (20 mg/m 2 in children) for 4 sequential days every 28 days-has been used with mixed success for chronic or refractory ITP. Although some studies reported good efficacy and low toxicity, 71, 72 others found mixed responses and significant toxicity (such as hypertension with stroke or insulin-dependent diabetes). 73 More recent studies suggest that high-dose dexamethasone may be more useful as a front-line agent for ITP rather than second-line therapy 74, 75 and that it may be worth trying before splenectomy in severe symptomatic chronic childhood ITP. 76, 77 Thrombopoeitin agonists are a novel class of ITPselective drugs may decrease the need for immunosuppressive or cytotoxic therapies. Eltrombopag (an oral small molecule agonist) and romiplostim (an Fc-peptide fusion protein) both target and activate the thrombopoeitin receptor on megakaryocytes. Each serves as a positive signal to stimulate marrow production of platelets. 78 One French study of adult ITP patients found that romiplostim caused platelet counts to rise to at least 50,000/mL in 74% of patients and that long-term responses of at least 2 years were observed in 65% of patients. 79 In general, thrombopoeitin agonists seem to be well tolerated in adults, but their safety in children has not yet been established. These agents are now being studied in children with ITP. 42, 78 SURGICAL MANAGEMENT-SPLENECTOMY Splenectomy has been recognized for nearly a century as being effective treatment for ITP. 80 As a reticuloendothelial organ rich with Fc receptor-expressing phagocytes, the spleen is the major site wherein antibodycoated (opsonized) platelets are actively removed from the circulation. 81 Thus, removal of the spleen leads to prolonged survival of opsonized platelets in the circulation. The spleen may also house plasma cells that produce antiplatelet antibodies, therefore, splenectomy may help eliminate the source of the errant autoantibodies that cause ITP. Although safer today because of better surgical (laparoscopic vs. open) and medical care, splenectomy is not without risk. 82, 83 Splenectomized patients have life-long enhanced risk of thrombosis 84 and infection. 85, 86 The spleen seems especially critical to the clearance of encapsulated organisms, therefore, asplenic patients are at risk of Haemophilus, Neisseria, and Pneumococcus sepsis [87] [88] [89] [90] and incidence of overwhelming sepsis postsplenectomy is on the order of 1% to 2%. 91 Asplenic patients are also at heightened risk of certain protozoal infections, especially malaria and babesiosis. 92, 93 As infectious risk is particularly high among very young children, 94 many practitioners defer splenectomy until a minimum of 5 years of age. Immunization against Haemophilus influenza type B, Meningococcus, and Pneumococcus is recommended preoperatively, and oral prophylactic antibiotic therapy (typically penicillin) is recommended postoperatively, as is appropriate sepsis evaluation for fever. 90, 95 Splenectomy is definitive treatment for most children with ITP, raising their platelet counts to normal or at least to levels that support liberalization of physical activities. In one pediatric study, splenectomy resulted in significant platelet increases in 85% of patients with chronic ITP. 83 In comparison, 50% to 60% of adults with chronic ITP respond to splenectomy. 96 Nonetheless, some patients will fail to respond, and some initial responders may have recurrence of thrombocytopenia after splenectomy. In a retrospective analysis of over 400 patients with ITP, 23% of splenectomy-responsive patients relapsed, in most cases (80%) within 2 years of the procedure. 82 Some ITP relapses have correlated with the presence of accessory spleens. 97 Patients and their families must understand the unpredictable effectiveness and inherent risks of splenectomy for ITP. The American Society of Hematology suggests that splenectomy should be considered for patients with chronic or persistent ITP who have significant bleeding symptoms, intolerance of medical therapy, or the need for improved quality of life. 1 
MANAGEMENT OF SERIOUS BLEEDING
The presence of significant hemorrhage in the setting of ITP is a true medical emergency and life-threatening or limb-threatening bleeding is an indication for interventions aimed at quickly raising platelet count and achieving hemostasis. Intracranial hemorrhage, for example, carries a mortality rate of nearly 50% in ITP patients. 12, 98 Medical management of serious bleeding will be dictated by clinical circumstances and may involve a variety of medical and surgical interventions tried alone or in combination. Massive or successive platelet transfusions, intravenous highdose corticosteroids, IVIg/WinRho, and plasmapheresis have all been described. [99] [100] [101] Efforts aimed to interfere directly with splenic function may also be useful. Thus, emergency splenectomies under "cover" of serial platelet transfusion or medical therapies such as high-dose steroid or IVIg treatment have been described. 102, 103 There is at least 1 case report of combination immunosuppressive therapy (cyclophosphamide, vincristine, and corticosteroids) in conjunction with frequent transfusions of platelets being used for life-threatening bleeding in a child with ITP. 104 Ligating or embolizing the splenic artery usually leads to profound increases in the circulating platelet counts, and may be performed before splenectomy to make resection of the spleen safer. 105 Fortunately, life-threatening bleeding is exceedingly rare in childhood ITP.
CONCLUSIONS
ITP is one of the most common hematologic disorders of childhood and adolescence. It is an autoimmune process characterized by the inappropriate production of antibodies directed against normal platelets and megakaryocytes. As a result of antibody binding, platelets and their precursors are destroyed, resulting in dramatic reductions in the numbers of circulating platelets. Clinically, this manifests as widespread appearance of cutaneous and mucosal petechiae and purpurae. A diagnosis of exclusion, most cases of ITP can be identified by a careful history, physical examination and limited blood work. Although classified as a benign process, ITP can have a profound on quality of life and interfere with normal childhood. Our clinical case demonstrates the course of 1 particular patient with ITP whose disease initially responded to therapy but then became therapyrefractory and chronic. A variety of medical approaches were tested until 1 combination (sirolumus with intermittent WinRho administration) was found that maintained the platelet count at a reasonable level. This case also demonstrates the fact that ITP can resolve in children even when has persisted for a long time. The ITP working group of the American Society of Hematology suggests that frontline management for children with ITP includes IVIg, a short course of corticosteroids or WinRho (Anti-D) therapy in Rh-positive non-anemic children. Preferred secondline medical approaches are rituximab or high-dose dexamethasone. Splenectomy is a very effective therapy for most patients, but because of life-long risks of infection and thrombosis, should generally be considered only after medical interventions have proven inadequate.
